

January 31, 2017

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Dear Sir/Madam,

Sub: Intimation of Conference Call for Investors/Analysts for Q3 & 9M FY 17.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Feb 02, 2017 at 5:00 PM IST to discuss the financial and operating performance for Q3 & 9M FY17.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary & Legal Head

Encl: As above

Q3 & 9M FY17 Earnings Conference Call Thursday, February 02, 2017 at 5:00 pm IST

Gurgaon, January 31, 2017:

Dr Lal PathLabs Ltd. (LPL) will be hosting a conference call to discuss its Q3 & 9M FY17 results. LPL will be represented by (Hony.) Brig. Dr. Arvind Lal - Chairman and Managing Director, Dr. Om Prakash Manchanda - Whole-time Director and CEO and Mr. Dilip Bidani - CFO.

The conference call will be initiated with a brief discussion by the management on the Q3 & 9M FY17 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none">• 05:00 pm IST on Thursday, February 02, 2017
Conference dial –in – India Access	<ul style="list-style-type: none">• +91 22 3938 1071 (Primary Number)
Local Access Number	<ul style="list-style-type: none">• 3940 3977 Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers.
Conference dial-in – International Toll Number	<ul style="list-style-type: none">• USA - 13233868721
	<ul style="list-style-type: none">• UK - 442034785524
	<ul style="list-style-type: none">• Singapore - 6531575746
	<ul style="list-style-type: none">• Hong Kong - 85230186877
Replay	<ul style="list-style-type: none">• +91 22 3065 2322• 19688 (passcode)• Valid from February 02, 2017 to February 09, 2017

-ENDS-

About Dr Lal PathLabs Limited (LPL)

Dr Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of LPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 1,110 test panels, 1,934 pathology tests and 1,561 radiology and cardiology tests.

As on March 31, 2016 LPL's has 172 clinical labs (including National Reference Lab at Delhi), 1,559 Patient Service Centers (PSCs) and 4,967 Pick-up Points (PUPs). In FY2015 and FY16, LPL collected and processed approximately 21.7 million samples and 26.3 million samples from approximately 9.9 million and 12 million patients, respectively.

Additional information on Dr Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

For further information please contact:

Dilip Bidani
Dr Lal PathLabs Limited
Tel: +91 124 301 6500
Fax: +91 124 423 4468
E-mail: dilip.bidani@lalpathlabs.com

Siddharth Rangnekar / Urvashi Butani
CDR, India
Tel: +91 22 66451209 / 1219
Fax: +91 22 66451213
Email: siddharth@cdr-india.com
urvashi@cdr-india.com